Xbrane Biopharma AB (XBRANE) — Net Asset Quality Index
Xbrane Biopharma AB (XBRANE) has a Net Asset Quality Index of 83.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Skr671.62 Million minus total liabilities of Skr110.97 Million yields net assets of Skr560.65 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Xbrane Biopharma AB to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xbrane Biopharma AB Net Asset Quality Index Over Time (2012–2025)
This chart shows how Xbrane Biopharma AB's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the index stands at 83.5%, representing net assets of Skr560.65 Million against total assets of Skr671.62 Million SEK. See XBRANE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see XBRANE stock market capitalisation.
| Year | Quality Index | Net Assets (SEK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.5% | Skr560.65 Million | Skr671.62 Million | Skr110.97 Million | ▲ +58.7 pp |
| 2024 | 24.8% | Skr208.54 Million | Skr842.43 Million | Skr633.89 Million | ▼ -1.5 pp |
| 2023 | 26.2% | Skr171.34 Million | Skr653.51 Million | Skr482.17 Million | ▼ -35.3 pp |
| 2022 | 61.5% | Skr424.89 Million | Skr690.51 Million | Skr265.63 Million | ▼ -1.2 pp |
| 2021 | 62.7% | Skr431.74 Million | Skr688.43 Million | Skr256.69 Million | ▲ +7.1 pp |
| 2020 | 55.6% | Skr257.71 Million | Skr463.76 Million | Skr206.06 Million | ▲ +1.2 pp |
| 2019 | 54.4% | Skr184.32 Million | Skr338.94 Million | Skr154.62 Million | ▲ +21.5 pp |
| 2018 | 32.8% | Skr83.07 Million | Skr252.88 Million | Skr169.81 Million | ▼ -46.8 pp |
| 2017 | 79.7% | Skr88.41 Million | Skr110.96 Million | Skr22.55 Million | ▼ -11.2 pp |
| 2016 | 90.8% | Skr107.30 Million | Skr118.11 Million | Skr10.81 Million | ▲ +27.8 pp |
| 2015 | 63.1% | Skr47.51 Million | Skr75.33 Million | Skr27.82 Million | ▼ -31.1 pp |
| 2014 | 94.2% | Skr6.30 Million | Skr6.69 Million | Skr390.70K | ▼ -0.3 pp |
| 2013 | 94.5% | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +81.1 pp |
| 2012 | 13.4% | Skr88.11K | Skr657.01K | Skr568.90K | — |